• Natera will expand its North Austin campus with a dedicated sequencing facility, targeting what it believes will be the world’s largest sequencing capacity.
• A second building in the same complex will add new lab space to support higher testing volumes, with oncology volumes up more than 54% year over year in the first quarter of 2026.
• The expansion is expected to create up to 400 new jobs across professional, laboratory, and operational roles.
• Signatera is used by more than 50% of U.S. oncologists, with Signatera CDx recently becoming the first FDA-approved companion diagnostic in molecular residual disease testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605210700BIZWIRE_USPR_____20260521_BW633963) on May 21, 2026, and is solely responsible for the information contained therein.